(Hypertension. 2002;39:865.)
© 2002 American Heart Association, Inc.
Scientific Contributions |
From the Laboratory of Cardiovascular Sciences, Gerontology Research Center, National Institute on Aging/National Institutes of Health, Baltimore, Md.
Correspondence to Edward G. Lakatta, MD, Laboratory of Cardiovascular Sciences, Gerontology Research Center, National Institute on Aging/National Institutes of Health, 5600 Nathan Shock Drive, 3-B-03, Baltimore, MD 21224-6825. E-mail lakattae{at}grc.nia.nih.gov
| Abstract |
|---|
|
|
|---|
Key Words: aging aorta extracellular matrix gene expression immunohistochemistry metalloprotease
| Introduction |
|---|
|
|
|---|
Recent evidence suggests that MMP-2, a zinc dependent endopeptidase,5 promotes matrix protein degradation in vascular disease remodeling,6 similar to its role in tumor invasion,7 and facilitates SMC migration.8 In the aged aortae, MMP-2 accumulates in the area surrounding SMCs that are located near breaks in the internal elastic lamina and along elastic laminae throughout the media,4 suggesting that MMP-2 may also have a role in fragmentation of the elastic laminae with aging.
The MMP zymogen is regulated by gene transcription, and a delicate balance among its activators and inhibitors controls its activation status9 and its potential impact on arterial remodeling. In fibroblasts,10 endothelial cells,11,12 and tumor cells,1315 cleavage and activation of MMP-2 is achieved by a novel membrane-type matrix metalloproteinase (MT1-MMP), synthesized as a pro-form and cleaved by both the intracellular protease furin16 and extracellular plasmin.17 An increased level of MT1-MMP and increased MMP-2 activation have been detected in the neointima following carotid injury.18
TIMP-2, an endogenous tissue inhibitor of MMP-2, acts directly to inhibit MMP-2 activation by binding to it and also binds to MT1-MMP, blocking its activation.19,20 Overexpression of TIMP-2 reduces neointimal hyperplasia following carotid arterial injury.21 The serine protease, plasmin, inactivates TIMP-2 and can also induce a complete conversion of proMMP-2 form to the active form.22 Tissue plasminogen activator (tPA) and urokinase plasminogen activator (uPA), through their binding to the endogenous uPA receptor (uPAR), facilitate the conversion of plasminogen to plasmin. ProMMP-2 activation is inhibited by plasmin inhibitors-1 (PAI-1) or anti-uPA antibodies.22,23
The present study provides evidence for an age-associated increase in the amount and activity of proMMP-2 in the aortic wall of aged rats, occurring in the context of an imbalance among MT1-MMP, TIMP-2, and factors within the plasminogen activation pathway.
| Materials and Methods |
|---|
|
|
|---|
Immunohistochemistry
Immunohistochemistry was performed according to the biotin-streptavidin kits instruction (Zymed Laboratories, Inc). Antigen was recovered in citrate buffer at pH 6.0 (Zymed Laboratories, Inc) for 1 to 3 minutes in a microwave oven. The slides were incubated overnight at 4°C with primary antibodies (Table 1).
|
In Situ Hybridization
Digoxigenin (DIG)-labeled MMP-2 (330 bp), TIMP-2 (361 bp), and MT1-MMP(2338 bp) riboprobes were obtained from plasmid cDNA (kindly provided by Michael Crow, Gerontology Research Center, Baltimore, Md) by standard RNA synthesis, using SP6, T7, or T3 RNA polymerase. Incorporation of DIG-conjugated uridine-5-triphosphate (UTP) was determined using a commercial kit (Boehringer Mannheim Corp) following the manufacturers instruction. In situ hybridization was performed by modification of the methods previously described.25 Corresponding sense probes, hybridization buffer without probes, and RNase digestion of tissue sections for 30 minutes before hybridization were used as controls to determine specific hybridization.
In Vitro and In Situ Zymography
Frozen aortae were extracted and assayed via electrophoretic gelatin zymography as previously described.4 Recombinant human active and inactive MMP-2 mixtures (Oncogene Research Products) were used as positive controls. Zymography was performed in the presence of an inhibitory antibody against MMP-2 to determine the enzymatic specificity of gel digestion.
Statistical Analyses
All results are expressed as the mean±SEM. Statistical comparisons for age differences were made via an ANOVA followed by Bonferoni post hoc tests. A P value of <0.05 was taken as statistically significant.
| Results |
|---|
|
|
|---|
|
|
Immunostaining for MMP-2, TIMP-2, and MT1-MMP
Figure 2 depicts representative aortic sections of each age group stained with antibodies against MMP-2, TIMP-2, or MT1-MMP. At 2 months of age, MMP-2 was rarely visualized within the intima. Between 2 and 8 months, both the intimal and medial MMP-2 staining increased, and further increased between 8;T3 and 30 months (Table 3). In contrast, TIMP-2 was abundantly expressed in the intima at all ages (Figure 2, middle panels). However, with increasing age, particularly between 8 and 30 months, the medial content of TIMP-2 became dramatically reduced (Figure 2 and Table 3). Thus, the relative intensities of staining pattern for MMP-2/TIMP-2 in both the intima and the media increased monotonically with age (Figure 3). Intimal MT1-MMP staining increased with age (Figure 2, right panels), and this increase was statistically significant between 8 and 30 months (Table 3). Medial MT1-MMP staining did not significantly change with age. Thus, the MT1-MMP/TIMP increased with age in both the intima and media (Figure 3).
|
|
|
Immunostaining for tPA, uPA, uPAR, and PAI-1
tPA was expressed mainly in the intima, and its staining became more intense with advancing age (Figure 4, left panels, and Table 3). PAI-1 was abundantly expressed in the intima and media; intimal PAI-1 did not change with age, but within the media decreased significantly between 2 and 8 and 8 and 30 months of age (Figure 4, right panels, and Table 3). There were no significant differences among 3 age groups in the tPA:PAI-1 within the intima (Figure 3), but this ratio increased with aging within the media. With advancing age, staining for uPA tended to increase in both the intima and media, but this trend was statistically significant only within the intima at 30 months. The medial, but not the intimal, uPA:PAI-1 increased significantly with age between 8 and 30 months, (Figure 3). In contrast, uPAR staining markedly increased with age in both compartments (Figure 4, Table 3).
|
In Situ Hybridization for MMP-2, TIMP-2, and MT1-MMP mRNA
MMP-2 mRNA was detected within intimal endothelial cells and medial SMC (Figure 5). The average staining for intimal MMP-2 mRNA was low at 2 months and increased with age (Table 4). TIMP-2 mRNA was detected in some intimal endothelial cells and medial SMC, with the staining localized within or around nuclei. Medial TIMP-2 mRNA decreased with age, with significant reductions occurring between 8 and 30 months (Figure 5, Table 4). MT1-MMP mRNA staining increased with age within both compartments, and this increase reached statistical significance between 2 and 30 months.
|
|
Measurement of Gelatinolytic Activity by In Vitro and In Situ Zymography
Figure 6 shows representative in vitro zymograms from each age group. A clear gelatinolytic 72 kDa band was present at 2 months. Clear and weak 72 kDa and 62 kDa bands, corresponding to pro and active forms of MMP-2, respectively, were detected at 8 months, and predominant 72 kDa and 62 kDa bands were detected at 30 months (Figure 6A). Densitometric quantification indicated no significant differences in proMMP-2 among 3 groups (Figure 6B); active MMP-2, however, increased 1.5-fold at 8 months compared with 2 months (P<0.05) and increased an additional 1.7-fold at 30 months (P<0.01).
|
Gelatinolysis during in situ zymography is indicated by green fluorescence against a dark background (Figure 7). The in situ gelatinolytic activity increased with age (Figure 7, middle panels) and was mainly localized to intima, internal elastic lamina, and elastin fibers in the inner tunica media. The in situ gelatinolytic activity was almost completely inhibited by an antibody against MMP-2 (Figure 7, right panels) demonstrating that it mainly resulted from MMP-2 activity. Aortic elastin also exhibits green autofluorescence, and control aortic sections clearly demonstrate the decrement of elastin density in the aged aorta (Figure 7, left panels).
|
| Discussion |
|---|
|
|
|---|
|
The observed imbalances in MMP-2:TIMP-2 and MT1-MMP: TIMP-2 and tPA, uPA:PAI-1, and the increased uPAR with aging, coupled to the increased level of total MMP-2 zymogen and increased MMP-2 activity, are likely candidate mechanisms for the observed age-associated increase in MMP-2 activity within the vessel wall. The age-associated increases in intimal or medial MMP-2 and MT1-MMP and the reduction in TIMP-2 are, in part, transcriptionally regulated, as suggested by an increase in the steady levels of intimal or medial mRNA for both MMP-2 and MT1-MMP and a reduction for that of TIMP-2. The basal production of MMP-2, which is typically low, is increased by factors such as cytokines, phorbol esters, or contact with components of the extracellular matrix. MMPs are synthesized in a latent form as pro-enzymes (zymogens) that are activated by proteolytic cleavage of an amino-terminal domain28 or independently of proteolytic processing by conformational changes such as those induced by oxidative stress.29 Factors relevant to the activation of proMMP-2 are produced by both endothelial cells and vascular smooth muscle cells.11,27,30,31 It is noteworthy that, in early passage, SMC from aortic explants, at MMP-2 production in response to stimulation by cytokines IL-1a, TNF-
, or TGF-ß, increases with age.32
Increased MMP activity may affect the vascular remodeling that accompanies aging in multiple ways. MMP-2 accumulates in SMC and elastic lamina (present study) and in the area surrounding smooth muscle cells located in the vicinity of breaks in the internal elastic lamina and along elastic laminae throughout the media of the aged aorta.4 Migration from the media is one plausible mechanism to account for the presence of SMC within the thickened intima of the aged aorta. Activated MMP-2, required for migrating cells to invade basement membrane, also requires dedifferentiation and lysis of their own basement membrane type IV collagen and invasion of the elastic lamellae and internal elastic membrane. The development of a synthetic, migratory phenotype of SMC in vitro occurs with successive culture passage and is accompanied by a high constitutive production of MMP-2;8 serum withdrawal reduces MMP production and prevents their invasion of basement membranes.8 Thus, increased MMP activity in situ may reflect an age-associated shift in some cells within the aortic media from the contractile to the synthetic-migratory phenotype. Additional evidence for in situ dedifferentiation of some aortic SMC with aging includes the observation that, unlike aortic medial SMC from young rats which in early passage in culture fail to migrate in response to a platelet-derived growth factor gradient, early-passaged aortic medial cells from old rats readily migrate in response to this stimulus.32
Protease dysregulation is a feature of in vitro cell senescence.33 In addition to increased protease activity within the aorta wall with aging, other markers of in vitro senescence in other cell types, including TGF-ß and ICAM, increase. Increased MMP activation induces the expression of the matrix glycoprotein, tenacin (TN),34 which has been linked to integrin ligation and induction of mitogen-activated protein kinase activity,35 SMC proliferation, and anti-apoptotic effect,34 each of which has been implicated in vascular diseases.36,37 Thus, the aging aortic wall is a heretofore relatively undiscovered in situ "petri dish," suitable for investigation of vascular smooth muscle dedifferentiation, proliferation, senescence, and apoptosis.
Perspectives
Age-associated remodeling of large vessels, manifest by intimal-medial thickening, dilation, stiffening, and endothelial dysfunction, occurs not only in rodents, but also in nonhuman primates, and in otherwise healthy humans as well. There is a growing body of evidence that increased arterial intimal-medial thickening, increased stiffness, and endothelial dysfunction in apparently otherwise healthy older persons, formerly thought to be part of "normal" aging, predict a higher risk for developing atherosclerosis, hypertension, stroke, and heart failure. In other words, aging blood vessels provide fertile soil in which vascular diseases can flourish, and this may explain, in part, why aging, per se, is so "risky" with respect to these diseases. The marked age-associated increase in arterial MMP-2 activity in situ, demonstrated here in rodents, which also occurs in nonhuman primates (Wang and Lakatta, unpublished observations, 2002), and other markers of vascular senescence observed in rodents, eg, increased TGF-ß and ICAM, are apparent mechanisms of the vascular remodeling that accompanies aging. Should similar mechanisms underlie age-associated arterial remodeling in humans, these would become potential targets, not only with respect to retarding "vascular aging," but also to reducing the marked risk that vascular aging, per se, confers for the development of human hypertension and atherosclerosis.
| Acknowledgments |
|---|
Received November 27, 2001; accepted February 21, 2002.
| References |
|---|
|
|
|---|
2.
Fornieri C, Quaglino D, Mori G. Role of the extracellular matrix in age-related modifications of the rat aorta. Arterioscler Thromb. 1992; 12: 10081016.
3. Haudenschild CC, Prescott MF, Chobanian AV. Aortic endothelial and subendothelial cells in experimental hypertension and aging. Hypertension. 1981; 3 (suppl I): I-148I-153.[Medline] [Order article via Infotrieve]
4.
Li Z, Froehlich J, Galis ZS., Lakatta EG. Increased expression of matrix metalloprtoeinase-2 (MMP-2) in the thickened intima of aged rats. Hypertension. 1999; 33: 116123.
5. Hooper NM. Families of zinc metalloproteinases. FEBS Lett. 1994; 354: 16.[CrossRef][Medline] [Order article via Infotrieve]
6. Woessner JF Jr. Matrix metalloproteinase and their inhibitors in connective tissue remodeling. FASEB J. 1991; 5: 21452154.[Abstract]
7. Stetler-Stevenson WG, Aznavoorian S, Liotta LA. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol. 1993; 9: 541573.[CrossRef][Medline] [Order article via Infotrieve]
8.
Pauly RR, Passaniti A, Bilato C, Monticone R, Cheng L, Papdaopoulos N, Gluzband Ya, Smith L, Weinstein C, Lakatta E, Crow MT. The migration of cultured vascular smooth muscle cells through a basement membrane barrier requires type IV collagenase activity and is inhibited by cellular differentiation. Circ Res. 1994; 75: 4154.
9.
Knox JB, Sukhova GK, Whittemore AD, Libby P. Evidence for altered balance between matrix metalloproteinases and their inhibitors in human aortic diseases. Circulation. 1997; 95: 205212.
10. Ward RV, Atkinson SJ, Slocombe PM, Docherty AJP, Reynolds JJ, Murphy G. Tissue inhibitor of metalloproteinases-2 inhibits the activation of 72 kDa progelatinase by fibroblast membranes. Biochim Biophys Acta. 1991; 1079: 242246.[CrossRef][Medline] [Order article via Infotrieve]
11.
Haas TL, Davis SJ, Madri JA. Three-dimensional type I collagen lattices induce coordinate expression of matrix metalloproteinases MT1-MMP and MMP-2 in microvascular endothelial cells. J Biol Chem. 1998; 273: 36043610.
12. Lewalle JM, Munaunt C, Pichot B, Cataldo D, Baramova E, Foidart JM. Plasma membrane-dependent activation of gelatinase A in human vascular endothelial cells. J Cell Physiol. 1995; 165: 475483.[CrossRef][Medline] [Order article via Infotrieve]
13.
Azzam HS, Arnard GA, Lippman ME, Thompson EW. Association of MMP-2 activation potential with metastatic progression in human breast cancer cell lines independent of MMP-2 production. J Natl Cancer Inst. 1993; 85: 17581764.
14. Brown PD, Kleiner DE, Unsworth EJ, Stetler-Stevenson WG. Cellular activation of the 72 kDa type IV procollagenase/TIMP-2 complex. Kidney Int. 1993; 43: 163170.[Medline] [Order article via Infotrieve]
15.
Beliën AT, Paganetti PA, Schwab ME. Membrane-type 1 matrix metalloprotease (MT1-MMP) enables invasive migration of glioma cells in central nervous system white matter. J Cell Biol. 1999; 144: 373384.
16.
Pei D, Weiss SJ. Transmembrane-deletion mutants of the membrane-type matrix metalloproteinase-1 process progelatinase A and express intrinsic matrix-degrading activity. J Biol Chem. 1996; 271: 91359140.
17. Okumura Y, Sato H, Seiki M, Kido H. Proteolytic activation of the precursor of membrane type 1 matrix metalloproteinase by human plasmin. A possible cell surface activator. FEBS Lett. 1997; 402: 181184.[CrossRef][Medline] [Order article via Infotrieve]
18.
Jenkins GM, Crow MT, Bilato C, Gluzband Y, Ryu WS, Li Z, Stetler-Stevenson WG, Nater C, Froehlich J, Lakatta EG, Cheng L. Increased expression of membrane type-matrix metalloproteinase and preferential localization of matrix metalloproteinase-2 in the neointima of balloon injured rat carotid arteries. Circulation. 1998; 97: 8290.
19.
Butler GS, Butler MJ, Atkinson SJ, Will H, Tamura T, van Westrum SS, Crabbe T, Clements J, dOrtho MP, Murphy G. The TIMP2 membrane type 1 metalloproteinase "receptor" regulates the concentration and efficient activation of progelatinase A. A kinetic study. J Biol Chem. 1998; 273: 871880.
20.
Zucker S, Drews M, Conner C, Foda HD, DeClerck YA, Langley KE, Bahou WF, Docherty AJP, Cao J. Tissue inhibitor of metalloproteinase-2 (TIMP-2) binds to the catalytic domain of the cell surface receptor, membrane type 1-matrix metalloproteinase 1 (MT1-MMP). J Biol Chem. 1998; 273: 12161222.
21.
Cheng L, Mantile G, Pauly R, Nater C, Felici A, Monticone R, Bilato C, Gluzband YA, Crow MT, Stetler-Stevenson W, Capogrossi MC. Adenovirus-mediated gene transfer of the human tissue inhibitor of metalloproteinase-2 blocks vascular smooth muscle cell invasiveness in vitro and modulates neointimal development in vivo. Circulation. 1998; 98: 21952201.
22. Baramova EN, Bajou K, Remacle A, LHoir C, Krell HW, Weidle UH, Noel A, Foidart JM. Involvement of PA/plasmin system in the processing of pro-MMP-9 and in the second step of pro-MMP-2 activation. FEBS Lett. 1997; 405: 157162.[CrossRef][Medline] [Order article via Infotrieve]
23. Baricos WH, Cortez SL, el-Dahr SS, Schnaper HW. ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP-2 cascade. Kidney Int. 1995; 47: 10391047.[Medline] [Order article via Infotrieve]
24. Junqueira LC, Bignolas G, Brentani RR. Picrosirus staining plus polarization microscopy, a specific method for collagen detection in tissue sections. Histochem J. 1979; 11: 447455.[CrossRef][Medline] [Order article via Infotrieve]
25.
Nakada M, Nakamura H, Ikeda E, Fujimoto N, Yamashita J, Sato H, Seiki M, Okada Y. Expression and tissue localization of membrane-type 1, 2, and 3 matrix metalloproteinases in human astrocytic tumors. Am J Pathol. 1999; 154: 417428.
26. Wang H, Keiser JA. Expression of membrane-type matrix metalloproteinase in rabbit neointimal tissue and its correlation with matrix-metalloproteinase-2 activation. J Vasc Res. 1998; 35: 4554.[CrossRef][Medline] [Order article via Infotrieve]
27.
Raghunath PN, Tomaszewski JE, Brady ST, Caron RJ, Okada SS, Barnathan ES. Plasminogen activator system in human coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 1995; 15: 14321443.
28. Birkedal-Hansen H. Proteolytic remodeling of extracellular matrix. Curr Opin Cell Biol. 1995; 7: 728735.[CrossRef][Medline] [Order article via Infotrieve]
29. Okamoto T, Akaike T, Nagano T, Miyajima S, Suga M, Ando M, Ichimori K, Maeda H. Activation of human neutrophil procollagenase by nitrogen dioxide and peroxynitrite: a novel mechanism for procollagenase activation involving nitric oxide. Arch Biochem Biophys. 1997; 342: 261274.[CrossRef][Medline] [Order article via Infotrieve]
30.
Galis ZS, Kranzhofer R, Fenton JW2nd, Libby P. Thrombin promotes activation of matrix metalloproteinase-2 produced by cultured vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 1997; 17: 483489.
31.
Lijnen HR, Van Hoef B, Lupu F, Moons L, Carmeliet P, Collen D. Function of the plasminogen/plasmin and matrix metalloproteinase systems after vascular injury in mice with targeted inactivation of fibrinolytic system genes. Arterioscler Thromb Vasc Biol. 1998; 18: 10351045.
32. Li Z, Cheng H, Lederer WJ, Froehlich J, Lakatta EG. Enhanced proliferation and migration and altered cytoskeletal proteins in early passage smooth muscle cells from young and old rat aortic explants. Exp Mol Pathol. 1997; 64: 111.[CrossRef][Medline] [Order article via Infotrieve]
33. Campisi J. Aging and cancer: the double edged sword of replicative senescence. J Am Geriatr Soc. 1997; 45: 482488.[Medline] [Order article via Infotrieve]
34.
Jones PL, Crack J, Rabinovitch M. Regulation of tenascin-C, a vascular smooth muscle cell survival factor that interacts with the
vß3 integrin to promote epidermal growth factor receptor phosphorylation and growth. J Cell Biol. 1997; 139: 279293.
35. Jones PL, Jones FS, Zhou B, Rabinovitch M. Denatured type I collagen is dependent upon a ß3 integrinmediated mitogen-activated protein kinase pathway and a 122 base pair promoter element. J Cell Sci. 1999; 112: 435445.[Abstract]
36. Hedin U, Holm J, Hansson GK. Induction of tenascin-C in rat arterial injury: relationship to altered smooth muscle cells phenotype. Am J Pathol. 1991; 139: 649656.[Abstract]
37. Jones PL, Cowan K, Rabinovitch M. Tenascin-C, proliferation and subendothelial accumulation of fibronectin in progressive pulmonary vascular disease. Am J Pathol. 1997; 150: 13491360.[Abstract]
This article has been cited by other articles:
![]() |
B. Reel, G. Oktay, S. Ozkal, H. Islekel, E. Ozer, G. Ozsarlak-Sozer, Z. Cavdar, S. T. Akhisaroglu, and Z. Kerry MMP-2 and MMP-9 Alteration in Response to Collaring in Rabbits: The Effects of Endothelin Receptor Antagonism Journal of Cardiovascular Pharmacology and Therapeutics, December 1, 2009; 14(4): 292 - 301. [Abstract] [PDF] |
||||
![]() |
I. M. Porto, L. B. Rocha, M. A. Rossi, and R. F. Gerlach In Situ Zymography and Immunolabeling in Fixed and Decalcified Craniofacial Tissues J. Histochem. Cytochem., July 1, 2009; 57(7): 615 - 622. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. R. Lawrence and K. J. Gooch Transmural pressure and axial loading interactively regulate arterial remodeling ex vivo Am J Physiol Heart Circ Physiol, July 1, 2009; 297(1): H475 - H484. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Fu, M. Wang, M. Gucek, J. Zhang, J. Wu, L. Jiang, R. E. Monticone, B. Khazan, R. Telljohann, J. Mattison, et al. Milk Fat Globule Protein Epidermal Growth Factor-8: A Pivotal Relay Element Within the Angiotensin II and Monocyte Chemoattractant Protein-1 Signaling Cascade Mediating Vascular Smooth Muscle Cells Invasion Circ. Res., June 19, 2009; 104(12): 1337 - 1346. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. M. Sheridan, M. J. Ferguson, M. R. Distasi, F. A. Witzmann, M. C. Dalsing, S. J. Miller, and J. L. Unthank Impact of genetic background and aging on mesenteric collateral growth capacity in Fischer 344, Brown Norway, and Fischer 344 x Brown Norway hybrid rats Am J Physiol Heart Circ Physiol, December 1, 2007; 293(6): H3498 - H3505. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Misra, H. Lee, A. Singh, K. Huang, R. K. Thimmulappa, W. Mitzner, S. Biswal, and C. G. Tankersley Global expression profiles from C57BL/6J and DBA/2J mouse lungs to determine aging-related genes Physiol Genomics, November 14, 2007; 31(3): 429 - 440. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Miller, W. C. Watson, K. A. Kerr, C. A. Labarrere, N. X. Chen, M. A. Deeg, and J. L. Unthank Development of progressive aortic vasculopathy in a rat model of aging Am J Physiol Heart Circ Physiol, November 1, 2007; 293(5): H2634 - H2643. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Wang, J. Zhang, L.-Q. Jiang, G. Spinetti, G. Pintus, R. Monticone, F. D. Kolodgie, R. Virmani, and E. G. Lakatta Proinflammatory Profile Within the Grossly Normal Aged Human Aortic Wall Hypertension, July 1, 2007; 50(1): 219 - 227. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Schmoker, K. J. McPartland, E. K. Fellinger, J. Boyum, L. Trombley, F. P. Ittleman, C. Terrien III, A. Stanley, and A. Howard Matrix metalloproteinase and tissue inhibitor expression in atherosclerotic and nonatherosclerotic thoracic aortic aneurysms J. Thorac. Cardiovasc. Surg., January 1, 2007; 133(1): 155 - 161. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Wang, D. Zhao, G. Spinetti, J. Zhang, L.-Q. Jiang, G. Pintus, R. Monticone, and E. G. Lakatta Matrix Metalloproteinase 2 Activation of Transforming Growth Factor-{beta}1 (TGF-{beta}1) and TGF-{beta}1-Type II Receptor Signaling Within the Aged Arterial Wall Arterioscler Thromb Vasc Biol, July 1, 2006; 26(7): 1503 - 1509. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Paini, P. Boutouyrie, D. Calvet, A.-I. Tropeano, B. Laloux, and S. Laurent Carotid and Aortic Stiffness: Determinants of Discrepancies Hypertension, March 1, 2006; 47(3): 371 - 376. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Wang, J. Zhang, G. Spinetti, L.-Q. Jiang, R. Monticone, D. Zhao, L. Cheng, M. Krawczyk, M. Talan, G. Pintus, et al. Angiotensin II Activates Matrix Metalloproteinase Type II and Mimics Age-Associated Carotid Arterial Remodeling in Young Rats Am. J. Pathol., November 1, 2005; 167(5): 1429 - 1442. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. K. Natoli, T. L. Medley, A. A. Ahimastos, B. G. Drew, D. J. Thearle, R. J. Dilley, and B. A. Kingwell Sex Steroids Modulate Human Aortic Smooth Muscle Cell Matrix Protein Deposition and Matrix Metalloproteinase Expression Hypertension, November 1, 2005; 46(5): 1129 - 1134. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. S. Najjar, A. Scuteri, and E. G. Lakatta Arterial Aging: Is It an Immutable Cardiovascular Risk Factor? Hypertension, September 1, 2005; 46(3): 454 - 462. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A. Ahimastos, A. K. Natoli, A. Lawler, P. A. Blombery, and B. A. Kingwell Ramipril Reduces Large-Artery Stiffness in Peripheral Arterial Disease and Promotes Elastogenic Remodeling in Cell Culture Hypertension, June 1, 2005; 45(6): 1194 - 1199. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Yamamoto, K. Takeshita, T. Kojima, J. Takamatsu, and H. Saito Aging and plasminogen activator inhibitor-1 (PAI-1) regulation: implication in the pathogenesis of thrombotic disorders in the elderly Cardiovasc Res, May 1, 2005; 66(2): 276 - 285. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Spinetti, M. Wang, R. Monticone, J. Zhang, D. Zhao, and E. G. Lakatta Rat Aortic MCP-1 and Its Receptor CCR2 Increase With Age and Alter Vascular Smooth Muscle Cell Function Arterioscler Thromb Vasc Biol, August 1, 2004; 24(8): 1397 - 1402. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. M. Frederiks and O. R.F. Mook Metabolic Mapping of Proteinase Activity with Emphasis on In Situ Zymography of Gelatinases: Review and Protocols J. Histochem. Cytochem., June 1, 2004; 52(6): 711 - 722. [Abstract] [Full Text] [PDF] |
||||
![]() |
B.A. Kelly, B.C. Bond, and L. Poston Aortic adaptation to pregnancy: elevated expression of matrix metalloproteinases-2 and -3 in rat gestation Mol. Hum. Reprod., May 1, 2004; 10(5): 331 - 337. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Reed and J. M. Edelberg Impaired Angiogenesis in the Aged Sci. Aging Knowl. Environ., February 18, 2004; 2004(7): pe7 - 7. [Abstract] [Full Text] |
||||
![]() |
T. Koike, R. B. Vernon, M. D. Gooden, E. Sadoun, and M. J. Reed Inhibited Angiogenesis in Aging: A Role for TIMP-2 J Gerontol A Biol Sci Med Sci, September 1, 2003; 58(9): B798 - B805. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Wang, G. Takagi, K. Asai, R. G. Resuello, F. F. Natividad, D. E. Vatner, S. F. Vatner, and E. G. Lakatta Aging Increases Aortic MMP-2 Activity and Angiotensin II in Nonhuman Primates Hypertension, June 1, 2003; 41(6): 1308 - 1316. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Yan and E. A. G. Blomme In Situ Zymography: A Molecular Pathology Technique to Localize Endogenous Protease Activity in Tissue Sections Veterinary Pathology, May 1, 2003; 40(3): 227 - 236. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. G. Lakatta Arterial and Cardiac Aging: Major Shareholders in Cardiovascular Disease Enterprises: Part III: Cellular and Molecular Clues to Heart and Arterial Aging Circulation, January 28, 2003; 107(3): 490 - 497. [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2002 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |